Department of Internal Medicine, University of Utah, Salt Lake City, UT, USA.
Future Microbiol. 2013 Jun;8(6):769-83. doi: 10.2217/fmb.13.47.
Viruses of bacteria, known as bacteriophages or phages, were discovered nearly 100 years ago. Their potential as antibacterial agents was appreciated almost immediately, with the first 'phage therapy' trials predating Fleming's discovery of penicillin by approximately a decade. In this review, we consider phage therapy that can be used for treating bacterial infections in humans, domestic animals and even biocontrol in foods. Following an overview of the topic, we explore the common practice - both experimental and, in certain regions of the world, clinical - of mixing therapeutic phages into cocktails consisting of multiple virus types. We conclude with a discussion of the commercial and medical context of phage cocktails as therapeutic agents. In comparing off-the-shelf versus custom approaches, we consider the merits of a middle ground, which we deem 'modifiable'. Finally, we explore a regulatory framework for such an approach based on an influenza vaccine model.
细菌病毒，又称噬菌体或噬体，在近 100 年前被发现。它们作为抗菌剂的潜力几乎是立即被认识到的，第一批“噬菌体疗法”试验比弗莱明发现青霉素早了大约十年。在这篇综述中，我们考虑了可以用于治疗人类、家畜甚至食品生物防治中细菌感染的噬菌体疗法。在概述了这个主题之后，我们探讨了混合治疗噬菌体的常见实践——包括实验和在世界某些地区的临床实践——将多种病毒类型混合成鸡尾酒。我们以讨论噬菌体鸡尾酒作为治疗剂的商业和医疗背景结束。在比较现货供应和定制方法时，我们考虑了中间立场的优点，我们认为这是“可修改的”。最后，我们根据流感疫苗模型探索了这种方法的监管框架。
